284 related articles for article (PubMed ID: 33910629)
1. Molecular testing for cytologically suspicious and malignant (Bethesda V and VI) thyroid nodules to optimize the extent of surgical intervention: a retrospective chart review.
Hier J; Avior G; Pusztaszeri M; Krasner JR; Alyouha N; Forest VI; Hier MP; Mlynarek A; Richardson K; Sadeghi N; Tamilia M; Payne RJ
J Otolaryngol Head Neck Surg; 2021 Apr; 50(1):29. PubMed ID: 33910629
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of Preoperative Molecular Testing and Implications for Initial Surgical Management in Thyroid Nodules Harboring Suspected (Bethesda V) or Known (Bethesda VI) Papillary Thyroid Cancer.
Schumm MA; Shu ML; Hughes EG; Nikiforov YE; Nikiforova MN; Wald AI; Lechner MG; Tseng CH; Sajed DP; Wu JX; Yeh MW; Livhits MJ
JAMA Otolaryngol Head Neck Surg; 2023 Aug; 149(8):735-742. PubMed ID: 37382944
[TBL] [Abstract][Full Text] [Related]
3. Molecular Profiling for Bethesda III to VI Nodules: Results of a Multicenter International Retrospective Study.
Morand GB; Tessler I; Noik M; Krasner J; Yamin T; Pusztaszeri MP; Avior G; Payne RJ
Endocr Pract; 2024 Apr; 30(4):319-326. PubMed ID: 38184241
[TBL] [Abstract][Full Text] [Related]
4. Molecular Genetics Augment Cytopathologic Evaluation and Surgical Planning of Pediatric Thyroid Nodules.
Spaulding SL; Maayah M; Dinauer CA; Prasad M; Darbinyan A; Morotti R; Christison-Lagay ER
J Pediatr Surg; 2024 May; 59(5):975-980. PubMed ID: 38246817
[TBL] [Abstract][Full Text] [Related]
5. Association of Bethesda category and molecular mutation in patients undergoing thyroidectomy.
Mascarella MA; Peeva M; Forest VI; Pusztaszeri MP; Avior G; Tamilia M; Mlynarek AM; Hier MP; Payne RJ
Clin Otolaryngol; 2022 Jan; 47(1):75-80. PubMed ID: 34510770
[TBL] [Abstract][Full Text] [Related]
6. Malignancy rates for Bethesda III and IV thyroid nodules: a retrospective study of the correlation between fine-needle aspiration cytology and histopathology.
Yaprak Bayrak B; Eruyar AT
BMC Endocr Disord; 2020 Apr; 20(1):48. PubMed ID: 32293401
[TBL] [Abstract][Full Text] [Related]
7. Preoperative Role of RAS or BRAF K601E in the Guidance of Surgery for Indeterminate Thyroid Nodules.
Ravella L; Lopez J; Descotes F; Giai J; Lapras V; Denier ML; Borson-Chazot F; Lifante JC; Decaussin-Petrucci M
World J Surg; 2020 Jul; 44(7):2264-2271. PubMed ID: 32227276
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic Lobectomy for Bethesda III Thyroid Nodules: Pathological Outcomes and Risk Factors for Malignancy.
Walters BK; Garrett SL; Aden JK; Williams GM; Butler-Garcia SL; Newberry TR; Mckinlay AJ
Ann Otol Rhinol Laryngol; 2021 Sep; 130(9):1064-1068. PubMed ID: 33567896
[TBL] [Abstract][Full Text] [Related]
9. Rates of Malignancy in Cytology Indeterminate Thyroid Nodules: A Single Center Surgical Series.
Baraf L; Avidor Y; Bahat Dinur A; Yoel U; Samueli B; Joshua BZ; Fraenkel M
Isr Med Assoc J; 2023 Feb; 25(2):147-151. PubMed ID: 36841986
[TBL] [Abstract][Full Text] [Related]
10. Molecular mutations as a possible factor for determining extent of thyroid surgery.
Krasner JR; Alyouha N; Pusztaszeri M; Forest VI; Hier MP; Avior G; Payne RJ
J Otolaryngol Head Neck Surg; 2019 Oct; 48(1):51. PubMed ID: 31623671
[TBL] [Abstract][Full Text] [Related]
11. Association of Tumor Size With Histologic and Clinical Outcomes Among Patients With Cytologically Indeterminate Thyroid Nodules.
Valderrabano P; Khazai L; Thompson ZJ; Otto KJ; Hallanger-Johnson JE; Chung CH; Centeno BA; McIver B
JAMA Otolaryngol Head Neck Surg; 2018 Sep; 144(9):788-795. PubMed ID: 30027226
[TBL] [Abstract][Full Text] [Related]
12. The role of repeat fine needle aspiration in the management of indeterminate thyroid nodules.
Jooya A; Saliba J; Blackburn A; Tamilia M; Hier MP; Mlynarek A; Forest VI; Rochon L; Florea A; Wang H; Payne RJ
J Otolaryngol Head Neck Surg; 2016 Oct; 45(1):51. PubMed ID: 27756425
[TBL] [Abstract][Full Text] [Related]
13. Effect of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP) on Malignancy Rates in Thyroid Nodules: How to Counsel Patients on Extent of Surgery.
Lindeman BM; Nehs MA; Angell TE; Alexander EK; Gawande AA; Moore FD; Doherty GM; Cho NL
Ann Surg Oncol; 2019 Jan; 26(1):93-97. PubMed ID: 30341576
[TBL] [Abstract][Full Text] [Related]
14. Afirma Genomic Sequencing Classifier and Xpression Atlas Molecular Findings in Consecutive Bethesda III-VI Thyroid Nodules.
Hu MI; Waguespack SG; Dosiou C; Ladenson PW; Livhits MJ; Wirth LJ; Sadow PM; Krane JF; Stack BC; Zafereo ME; Ali SZ; Weitzman SP; Hao Y; Babiarz JE; Kennedy GC; Kloos RT
J Clin Endocrinol Metab; 2021 Jul; 106(8):2198-2207. PubMed ID: 34009369
[TBL] [Abstract][Full Text] [Related]
15. ACR TI-RADS and ATA US scores are helpful for the management of thyroid nodules with indeterminate cytology.
Barbosa TLM; Junior COM; Graf H; Cavalvanti T; Trippia MA; da Silveira Ugino RT; de Oliveira GL; Granella VH; de Carvalho GA
BMC Endocr Disord; 2019 Oct; 19(1):112. PubMed ID: 31664992
[TBL] [Abstract][Full Text] [Related]
16. Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice.
Witt RL
Del Med J; 2016 Dec; 88(12):366-372. PubMed ID: 29461717
[TBL] [Abstract][Full Text] [Related]
17. Preoperative cytology with molecular analysis to help guide surgery for pediatric thyroid nodules.
Buryk MA; Monaco SE; Witchel SF; Mehta DK; Gurtunca N; Nikiforov YE; Simons JP
Int J Pediatr Otorhinolaryngol; 2013 Oct; 77(10):1697-700. PubMed ID: 23993207
[TBL] [Abstract][Full Text] [Related]
18. Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study.
Steward DL; Carty SE; Sippel RS; Yang SP; Sosa JA; Sipos JA; Figge JJ; Mandel S; Haugen BR; Burman KD; Baloch ZW; Lloyd RV; Seethala RR; Gooding WE; Chiosea SI; Gomes-Lima C; Ferris RL; Folek JM; Khawaja RA; Kundra P; Loh KS; Marshall CB; Mayson S; McCoy KL; Nga ME; Ngiam KY; Nikiforova MN; Poehls JL; Ringel MD; Yang H; Yip L; Nikiforov YE
JAMA Oncol; 2019 Feb; 5(2):204-212. PubMed ID: 30419129
[TBL] [Abstract][Full Text] [Related]
19. Does bethesda category predict aggressive features in malignant thyroid nodules?
Kleiman DA; Beninato T; Soni A; Shou Y; Zarnegar R; Fahey TJ
Ann Surg Oncol; 2013 Oct; 20(11):3484-90. PubMed ID: 23812773
[TBL] [Abstract][Full Text] [Related]
20. Significance of BRAF V600E Mutation and Cytomorphological Features for the Optimization of Papillary Thyroid Cancer Diagnostics in Cytologically Indeterminate Thyroid Nodules.
Beiša A; Kvietkauskas M; Beiša V; Stoškus M; Ostanevičiūtė E; Jasiūnas E; Griškevičius L; Šeinin D; Šileikytė A; Strupas K
Exp Clin Endocrinol Diabetes; 2019 Apr; 127(4):247-254. PubMed ID: 29566402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
